Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Raised by XTX Topco Ltd

XTX Topco Ltd raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 310.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 63,634 shares of the biotechnology company's stock after purchasing an additional 48,131 shares during the period. XTX Topco Ltd owned about 0.07% of Rocket Pharmaceuticals worth $800,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in shares of Rocket Pharmaceuticals by 796.2% in the fourth quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company's stock valued at $690,000 after purchasing an additional 48,793 shares in the last quarter. Jennison Associates LLC grew its holdings in Rocket Pharmaceuticals by 72.6% during the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company's stock valued at $884,000 after buying an additional 29,564 shares during the last quarter. Mirador Capital Partners LP increased its position in Rocket Pharmaceuticals by 403.9% during the fourth quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company's stock worth $1,063,000 after buying an additional 67,755 shares in the last quarter. Sovran Advisors LLC acquired a new position in shares of Rocket Pharmaceuticals in the fourth quarter worth $1,895,000. Finally, Strategic Financial Concepts LLC purchased a new stake in shares of Rocket Pharmaceuticals in the fourth quarter valued at $141,000. Institutional investors and hedge funds own 98.39% of the company's stock.

Analyst Ratings Changes

RCKT has been the topic of a number of recent research reports. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a report on Monday, December 30th. They issued an "outperform" rating and a $32.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They set an "outperform" rating and a $50.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of Rocket Pharmaceuticals in a research report on Wednesday, April 9th. Scotiabank lifted their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a report on Monday, March 3rd. Finally, Chardan Capital lowered their price target on Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Insider Activity at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Kinnari Patel purchased 21,099 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $4.70 per share, with a total value of $99,165.30. Following the acquisition, the insider now owns 26,774 shares of the company's stock, valued at $125,837.80. The trade was a 371.79 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $5.29, for a total transaction of $39,616.81. Following the completion of the transaction, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. This represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 28.50% of the company's stock.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ RCKT traded down $0.19 during trading on Tuesday, reaching $6.98. The stock had a trading volume of 835,726 shares, compared to its average volume of 1,292,382. The firm's 50 day moving average price is $7.91 and its two-hundred day moving average price is $11.59. Rocket Pharmaceuticals, Inc. has a one year low of $4.55 and a one year high of $26.98. The stock has a market cap of $744.38 million, a PE ratio of -2.53 and a beta of 1.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. On average, research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.